Legato Capital Management LLC Lowers Stock Holdings in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Legato Capital Management LLC reduced its position in ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) by 23.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 122,057 shares of the company's stock after selling 36,911 shares during the quarter. Legato Capital Management LLC owned about 0.44% of ClearPoint Neuro worth $1,877,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Barclays PLC grew its holdings in shares of ClearPoint Neuro by 24.3% during the 3rd quarter. Barclays PLC now owns 5,674 shares of the company's stock worth $64,000 after purchasing an additional 1,109 shares during the period. R Squared Ltd purchased a new position in ClearPoint Neuro during the 4th quarter valued at about $32,000. Parsons Capital Management Inc. RI boosted its holdings in ClearPoint Neuro by 1.9% during the 4th quarter. Parsons Capital Management Inc. RI now owns 141,573 shares of the company's stock valued at $2,177,000 after acquiring an additional 2,600 shares during the period. JPMorgan Chase & Co. boosted its holdings in ClearPoint Neuro by 58.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company's stock valued at $110,000 after acquiring an additional 3,612 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in ClearPoint Neuro by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 287,294 shares of the company's stock valued at $3,222,000 after acquiring an additional 4,170 shares during the period. 30.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Lake Street Capital increased their price target on ClearPoint Neuro from $17.00 to $30.00 and gave the company a "buy" rating in a research report on Tuesday, January 21st. B. Riley increased their price target on ClearPoint Neuro from $15.00 to $20.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th.

ClearPoint Neuro Price Performance

Shares of NASDAQ CLPT traded down $0.06 during midday trading on Friday, hitting $18.32. 121,954 shares of the company's stock were exchanged, compared to its average volume of 215,278. ClearPoint Neuro, Inc. has a twelve month low of $5.11 and a twelve month high of $19.22. The company has a market cap of $505.27 million, a PE ratio of -26.55 and a beta of 1.03. The firm's fifty day simple moving average is $16.42 and its 200-day simple moving average is $13.20.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.